gilead news - Search News

Gilead withdraws bladder cancer drug in US

Gilead withdraws bladder cancer drug in US after failed trial

Gilead Sciences said on Friday it was voluntarily withdrawing the U.S. approval for Trodelvy in previously treated patients with a type of urothelial cancer after consultation with the regulator.

Gilead Withdraws ADC Trodelvy in Bladder Cancer After Trial Failure

The move is a blow to Gilead’s cancer portfolio. Trodelvy, an antibody-drug conjugate granted accelerated approval for bladder cancer in 2021, failed its confirmatory trial earlier this year.

YAHOO!Finance · 2d

After Failed Confirmatory Trial, Gilead Withdraws US Accelerated Approval Of Trodelvy As Bladder Cancer treatment

On Friday, Gilead Sciences, Inc. (NASDAQ:GILD) announced plans to voluntarily withdraw the U.S. accelerated approval for Trodelvy (sacituzumab govitecan-hziy; SG) for adult patients with locally advanced or metastatic urothelial cancer who have previously received platinum-containing chemotherapy and either programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor.

8h

Gilead, Merck announce from Phase 2 islatravir/lenacapavir combo study

Gilead Sciences (GILD) and Merck (MRK) announced new results from a Phase 2 clinical study evaluating the investigational combination of ...

Business Wire21h

Gilead and Merck Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapav…

Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today ...

Gilead pulls Trodelvy's approval in bladder cancer after trial flop, FDA discussions

Trodelvy’s next big readout is EVOKE-03, which is testing the Gilead drug with Merck’s PD-1 inhibitor Keytruda in PD-L1-high ...

15h

Gilead And Merck Report Phase 2 Results For Islatravir And Lenacapavir Combination In HIV Treatment

Gilead Sciences Inc. (GILD) and Merck & Co Inc.(MRK) announced new results from a Phase 2 clinical study evaluating the ...

Zacks.com on MSN3d

Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know

Gilead Sciences (GILD) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some ...

With Gilead coming fast, GSK bolsters case for long-acting HIV PrEP drug Apretude

With Gilead sprinting to a likely approval next year for its long-acting pre-exposure | With GSK girding for competition from ...

ENDPOINTS NEWS2d

Gilead pulls Trodelvy's accelerated label in bladder cancer after drug failed confirmatory study

Gilead is withdrawing the accelerated approval for its blockbuster antibody-drug conjugate Trodelvy for bladder cancer after ...

4d

Lilly, Gilead, Amgen started at outperform by Bernstein

As for Lilly ( LLY ), Bernstein said its outperform rating “hinges on what they can do with the cash they generate from ...

Mount Gilead Firefighters to Be Honored by NC Insurance Commissioner During 100-Year Department Celebration

NC Insurance Commissioner Mike Causey honors 7 veteran Mount Gilead firefighters during the department's 100-year celebration ...

1don MSN

Goldman Sachs: Gilead Sciences, Inc. (NASDAQ:GILD) Is A Stock With High Consensus ROE

We recently looked at Goldman Sachs’ Stocks With Highest Consensus Returns: 42 Stocks With The Highest Consensus ROE. In this ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results